2014 JITC Best Paper Award Recipients

The Journal for ImmunoTherapy of Cancer (JITC) Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts. Papers published in the last 12 months authored by Society for Immunotherapy of Cancer (SITC) members were eligible for nomination for this award.

JITC Best Basic Science Paper

Articles nominated in this category present innovative research in basic medical sciences that have a direct relevance to future research in clinical medicine.

SprangerStefani_2014.jpgStefani Spranger, PhD
University of Chicago

"Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment"
Stefani Spranger, Holly K. Koblish, Brendan Horton, Peggy A. Scherle, Robert Newton and Thomas F. Gajewski

Journal for ImmunoTherapy of Cancer 2014 2:3

JITC Best Clinical/Translational Paper

Papers in this category present clinical research that has a clear potential to optimize patient care, with particular emphasis on high quality randomized controlled trials, novel combination treatments, therapies, novel diagnostic or prognostic insights and new insights into mechanism of action.

Bhatia-Shailender-cropped.jpgShailender Bhatia, MD
University of Washington

"Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase I/II study"
Shailender Bhatia, Brendan Curti, Marc S. Ernstoff, Michael Gordon, Elisabeth I. Heath, Wilson H. Miller Jr., Igor Puzanov, David I. Quinn, Thomas W. Flaig, Peter VanVeldhuizen, Kelly Byrnes-Blake, Jeremy A. Freeman, Rachel Bittner, Naomi Hunder, Sonia Souza and John A. Thompson

Journal for ImmunoTherapy of Cancer 2014 2:2